Lung Cancer
Conference Coverage
More liberal criteria could greatly expand clinical trial participation
CHICAGO – A proof-of-concept study suggests that broader inclusion criteria could nearly double participation in clinical trials for non–small...
Conference Coverage
Antibodies may have role in ‘TKI world’ of EGFR-mutant NSCLC
CHICAGO – Two antibody approaches showed promising preliminary activity and manageable safety, in studies designed to address the need for new...
News
FDA approves NovoTTF-100L System for advanced mesothelioma
The System delivers electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division and can be prescribed only by a...
From the Journals
Local consolidative therapy shows benefit in oligometastatic NSCLC
Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated...
From the Journals
Antiangiogenics linked to fatal bleeds after RT in patients with “ultracentral” lung tumors
Of six fatal pulmonary hemorrhages, four occurred in patients receiving bevacizumab or pazopanib within 30 days of stereotactic body radiation...
From the Journals
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
From the Journals
Younger patients with NSCLC tend to live longer
According to a retrospective analysis, younger patients with NSCLC had better survival, despite higher rates of brain metastasis and drive...
Opinion
PROs in lung cancer and how to administer trastuzumab
Dr. Alan P. Lyss explains what the PACIFIC and HannaH trials mean for your day-to-day practice.
Conference Coverage
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
ATLANTA – Investigators have identified factors associated with response to combination entinostat and pembrolizumab among NSCLC patients who...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...